Bayer appoints Bijoy Sagar as new Chief Information Technology & Digital Transformation Officer

Published On 2020-01-27 08:59 GMT   |   Update On 2020-01-27 08:59 GMT

Leverkusen:  Bijoy Sagar (50) will be Bayer's new Chief Information Technology & Digital Transformation Officer (CIDO) effective June 1, 2020. The move sees Daniel Hartert (61) leave Bayer after 12 years of service retiring from his corporate career. "In Bijoy, we have found a successor who will continue to drive forward our digital transformation and complete the transition we have initiated in IT," said Wolfgang Nickl, Chief Financial Officer of Bayer AG. "We would like to thank Daniel for his outstanding commitment and the way he has shaped our IT for over a decade. We wish him every success for the future."

"Now is a good time for me to hand over the reins and focus on other aspects of my life after more than 30 years of working at major corporations. The groundwork for the IT organization at Bayer has been laid, paving the way for Bijoy and the IT leadership team to take the digital transformation at Bayer to the next level," emphasized Hartert. Sagar will start at Bayer on April 1, 2020, giving him time to prepare for the task ahead and to ensure a smooth handover. In his new function, he will be reporting to the Chief Financial Officer.
Sagar is joining Bayer from U.S. medical technology company Stryker, where he was also a member of the executive team as Chief Digital Technology Officer. In these roles, he developed and implemented the company's digital strategy and was responsible for global IT. Sagar has worked for Stryker since 2014 and has over 20 years of experience in the healthcare and chemical sectors.
He has previously worked for pharma and biotech companies Millennium Pharmaceuticals, Amgen, Eli Lilly & Company and Merck KGaA. It was during his time in Merck KGaA that he gained professional experience in Switzerland and Germany. Sagar studied science at the University of Mumbai as well as Northeastern University, Boston and holds US citizenship.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News